Approximately 50% of patients with heart failure have heart failure with reduced ejection fraction (HFrEF). HFrEF morbidity and mortality are altered favorably with the use of guideline-directed medical therapy. Multiple drug therapies have informed evidence-based therapies for the treatment of HFrEF.
The authors of a scientific statement call for psychological health screening and treatment to be a part of caring for patients at risk for cardiovascular disease.
Supraventricular tachycardia (SVT) usually presents to the emergency department as a result of a combination of symptoms, including palpitations, dyspnea, and chest pain. Less frequent symptoms include lightheadedness, near-syncope, or syncope due to reduced cerebral perfusion. Accurate diagnosis of SVT guides acute treatment. Although many doctors are good at pattern recognition on electrocardiograms (ECGs), having a methodical approach to think through SVT is extremely helpful.
Supraventricular tachycardia (SVT) is a common medical condition. Diagnosis and treatment often occur simultaneously. To a great degree, long-term treatment options depend on the history of symptoms and the patient’s desire, rather than on the specific type of SVT.
This long-term, prospective study looks at changes in quantity of nut consumption and relative risk of cardiovascular disease and finds significantly lower risk when nut consumption increases by > 0.5 servings daily.
Hospitals that focus on collaboration between case management and transitional care clinics for people with congestive heart failure are finding positive outcomes in their patients’ health and 30-day readmissions.
Fortunately, pediatric heart failure is a rare occurrence, but early diagnosis, aggressive management, and timely transfer to a facility capable of advanced cardiac support are essential to optimize the outcome of each child. The authors review the early recognition of a child in heart failure and also discuss an approach to troubleshooting and recognizing complications associated with a ventricular assist device.
In a large, diverse cohort of Medicare patients hospitalized for heart failure exacerbations, almost half were on medications known to exacerbate heart failure; more than one-third were on these agents at discharge.